New Features information at Drug Development Technology New and updated information from Features listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Features information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif August’s top stories: Cancer Research UK’s new oncology trial, Novartis’ malaria drug trial http://www.drugdevelopment-technology.com/features/featureaugust-2017-top-news-stories-drug-5910400/ http://www.drugdevelopment-technology.com/features/featureaugust-2017-top-news-stories-drug-5910400/ Cancer Research UK initiated a trial of LY3143921 hydrate to treat patients with advanced solid tumours, and Novartis and MMV initiated a Phase IIb trial of KAF156 to treat multidrug-resistant malaria in Africa. Drugdevelopment-technology.com wraps u… Thu, 07 Sep 2017 15:02:00 GMT July’s top stories: NCI and COG’s paediatric precision cancer trial, AstraZeneca’s NSCLC trial results http://www.drugdevelopment-technology.com/features/featurejuly-2017-top-news-stories-drug-5887962/ http://www.drugdevelopment-technology.com/features/featurejuly-2017-top-news-stories-drug-5887962/ NIH’s unit NCI and the COG initiated patient enrolment in a paediatric Phase II clinical trial to evaluate targeted cancer medicines, and AstraZeneca reported positive results from the FLAURA trial of Tagrisso to treat patients with locally advanced … Sun, 06 Aug 2017 23:00:00 GMT June’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly’s empagliflozin trial http://www.drugdevelopment-technology.com/features/featurejunes-top-stories-nihs-phase-iii-trial-for-chikungunya-boehringer-and-lillys-empagliflozin-trial-5859422/ http://www.drugdevelopment-technology.com/features/featurejunes-top-stories-nihs-phase-iii-trial-for-chikungunya-boehringer-and-lillys-empagliflozin-trial-5859422/ A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic k… Tue, 04 Jul 2017 23:00:00 GMT May's top stories: Funders and NGOs agreed on new standards, Actinogen's Xanamem in Phase II http://www.drugdevelopment-technology.com/features/featuremays-top-stories-funders-ngos-agree-on-new-trial-standards-actinogens-xanamem-in-phase-ii-5825756/ http://www.drugdevelopment-technology.com/features/featuremays-top-stories-funders-ngos-agree-on-new-trial-standards-actinogens-xanamem-in-phase-ii-5825756/ Medical research funders and international NGOs agreed to implement the new WHO standards for clinical trials, and Actinogen Medical began patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer’s … Sun, 04 Jun 2017 23:00:00 GMT April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-niaids-phase-iiiib-zika-vaccine-trial-boehringers-nintedanib-in-phase-iii-5800076/ http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-niaids-phase-iiiib-zika-vaccine-trial-boehringers-nintedanib-in-phase-iii-5800076/ The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb clinical trial of a Zika vaccine, and Boehringer Ingelheim began patient enrolment in the Phase III PF-ILD trial of ninteda… Tue, 02 May 2017 23:00:00 GMT March's top stories: Cancer Research UK's pancreatic cancer trials, Novartis' Cosentyx in psoriasis http://www.drugdevelopment-technology.com/features/featuremarchs-top-stories-cancer-research-uks-pancreatic-cancer-trials-novartis-cosentyx-in-psoriasis-5778534/ http://www.drugdevelopment-technology.com/features/featuremarchs-top-stories-cancer-research-uks-pancreatic-cancer-trials-novartis-cosentyx-in-psoriasis-5778534/ Cancer Research UK invested £10m in the PRECISION Panc project, including a network of clinical trials for the treatment of pancreatic cancer, and Novartis reported positive results from the extension A2302E1 trial of Cosentyx to modify the course of… Mon, 03 Apr 2017 23:00:00 GMT February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial http://www.drugdevelopment-technology.com/features/featurefebruarys-top-stories-mercks-phase-iii-hiv-1-trial-results-nihs-phase-i-ags-v-vaccine-trial-5757057/ http://www.drugdevelopment-technology.com/features/featurefebruarys-top-stories-mercks-phase-iii-hiv-1-trial-results-nihs-phase-i-ags-v-vaccine-trial-5757057/ Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v… Tue, 07 Mar 2017 00:00:00 GMT January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk http://www.drugdevelopment-technology.com/features/featurejanuarys-top-stories-tg-therapeutics-has-begun-its-phase-ii-investigator-and-calcimedica-has-initiated-the-phase-i-safety-studies-5731135/ http://www.drugdevelopment-technology.com/features/featurejanuarys-top-stories-tg-therapeutics-has-begun-its-phase-ii-investigator-and-calcimedica-has-initiated-the-phase-i-safety-studies-5731135/ TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopm… Mon, 06 Feb 2017 00:00:00 GMT 2016: The year's biggest Drug Development Technology stories http://www.drugdevelopment-technology.com/features/feature2016-the-years-biggest-drug-development-technology-stories-5706284/ http://www.drugdevelopment-technology.com/features/feature2016-the-years-biggest-drug-development-technology-stories-5706284/ NIAID began a new HIV vaccine study in South Africa and Eli Lilly’s Phase III trial of Alzheimer disease drug failed. Drugdevelopment-technology wraps-up the key headlines from 2016. Tue, 03 Jan 2017 00:00:00 GMT November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-wellcomes-clinical-trial-network-eli-lillys-alzheimer-disease-drug-trial-5683416/ http://www.drugdevelopment-technology.com/features/featurenovembers-top-stories-wellcomes-clinical-trial-network-eli-lillys-alzheimer-disease-drug-trial-5683416/ UK’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November. Tue, 06 Dec 2016 00:00:00 GMT October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-eurocine-vaccines-influenza-vaccine-study-initiation-ivf-usage-leading-to-conceiving-male-child-5655728/ http://www.drugdevelopment-technology.com/features/featureoctobers-top-stories-eurocine-vaccines-influenza-vaccine-study-initiation-ivf-usage-leading-to-conceiving-male-child-5655728/ Eurocine Vaccines initiated a Phase I/II influenza vaccine study and a new study suggested in-vitro fertilisation increases the chances of conceiving a male child. Drugdevelopment-technology.com wraps up the key headlines from October 2016. Mon, 07 Nov 2016 00:00:00 GMT September's top stories: Oncternal begins TK216 trial, Medical cannabis trials begin in Canada http://www.drugdevelopment-technology.com/features/featureseptembers-top-stories-oncternal-begins-dosing-in-phase-i-trial-of-tk216-phase-ii-trial-of-medical-cannabis-in-canada-begin-5022063/ http://www.drugdevelopment-technology.com/features/featureseptembers-top-stories-oncternal-begins-dosing-in-phase-i-trial-of-tk216-phase-ii-trial-of-medical-cannabis-in-canada-begin-5022063/ Oncternal Therapeutics began dosing patients in its Phase I clinical trial of TK216 to treat Ewing sarcoma and Tilray and University of British Columbia began patient enrolment in Canada’s first Phase II clinical trial of medical cannabis to treat po… Thu, 06 Oct 2016 23:00:00 GMT August's top stories: Gradalis' Phase I breast cancer trial, Biothera and Merck conducted combination cancer immunotherapy trials http://www.drugdevelopment-technology.com/features/featureaugusts-top-stories-gradalis-phase-i-breast-cancer-trial-biothera-and-merck-to-conduct-combination-cancer-immunotherapy-trials-4996151/ http://www.drugdevelopment-technology.com/features/featureaugusts-top-stories-gradalis-phase-i-breast-cancer-trial-biothera-and-merck-to-conduct-combination-cancer-immunotherapy-trials-4996151/ Gradalis dosed the first patient in its pilot Phase I trial of a combination of Vigil Engineered Autologous Tumour Cells (EATCs) and durvalumab to treat advanced breast cancer, and Biothera collaborated with Merck to expand the ongoing clinical progr… Thu, 08 Sep 2016 23:00:00 GMT Pharma Technology Focus – Issue 50 http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-50-4988804/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-50-4988804/ In this issue: Maximising investment by cancer megafunds, positive clinical trials for an antibody to treat lupus, how copper can be used to tackle obesity, whether day and night should influence our drug regimes, a device to soak up excess drugs and… Thu, 25 Aug 2016 10:46:00 GMT July's top stories: GBT's Phase II1 trial GBT440, Merck's Phase III trial ONCEMRK of Isentress http://www.drugdevelopment-technology.com/features/featuredrugs-mins-july-4972093/ http://www.drugdevelopment-technology.com/features/featuredrugs-mins-july-4972093/ Global Blood Therapeutics (GBT) began the Phase IIa trial (GBT440-007) of GBT440 in adolescents with sickle cell disease (SCD), and Merck reported positive results from its ongoing Phase III pivotal trial ONCEMRK of Isentress (raltegravir) to treat a… Mon, 08 Aug 2016 23:00:00 GMT June's top stories: Bayer reported positive results of RESORCE trial, TapImmune initiated Phase II trial of TPIV 200 http://www.drugdevelopment-technology.com/features/featurejune-top-stories-bayers-positive-results-resorce-trial-tapimmunes-phase-ii-trial-tpiv-200-4939249/ http://www.drugdevelopment-technology.com/features/featurejune-top-stories-bayers-positive-results-resorce-trial-tapimmunes-phase-ii-trial-tpiv-200-4939249/ Bayer reported positive results from the Phase III RESORCE trial of Stivarga (regorafenib) tablets to treat unresectable hepatocellular carcinoma, and TapImmune initiated its Phase II trial of cancer vaccine TPIV 200. Drugdevelopment-technology.com w… Tue, 05 Jul 2016 23:00:00 GMT May's top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial http://www.drugdevelopment-technology.com/features/featuremays-top-stories-promedica-begin-human-stem-cell-trial-cerulean-doses-phase-lll-combination-trial-4907578/ http://www.drugdevelopment-technology.com/features/featuremays-top-stories-promedica-begin-human-stem-cell-trial-cerulean-doses-phase-lll-combination-trial-4907578/ ProMedica and Stemedica planned to begin a human stem cell trial for traumatic brain injury and Cerulean dosed its first patient in a Phase l/ll combination trial of CRLX101 and lynparza. Drugdevelopment-technology.com wraps up the key headlines from… Mon, 06 Jun 2016 23:00:00 GMT April's top stories: SynbiCITE's synthetic biology foundry, Omeros's phase II clinical trial of OMS721 http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-synbicites-synthetic-biology-foundry-omeross-phase-ii-clinical-trial-oms721-4876831/ http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-synbicites-synthetic-biology-foundry-omeross-phase-ii-clinical-trial-oms721-4876831/ SynbiCITE opened a commercial synthetic biology foundry at Imperial College London, and Omeros began dosing patients in its new Phase ll clinical trial of OMS721 in corticosteroid-dependent renal diseases. Drugdevelopment-technology.com wraps up the … Wed, 04 May 2016 23:00:00 GMT March's top stories: Tracon's Phase IbTRC105 clinical trial, ADC begins ADCT-402 trial http://www.drugdevelopment-technology.com/features/featuremarchs-top-stories-tracons-phase-ib-clinical-trial-of-trc105-adc-begins-adct-402-trial-4851960/ http://www.drugdevelopment-technology.com/features/featuremarchs-top-stories-tracons-phase-ib-clinical-trial-of-trc105-adc-begins-adct-402-trial-4851960/ Tracon Pharmaceuticals started Phase Ib clinical trial of TRC105, a clinical stage antibody to endoglin, and ADC Therapeutics began a Phase I trial of its antibody drug conjugate (ADC) ADCT-402. Drugdevelopment-technology.com wraps-up the key headlin… Mon, 04 Apr 2016 23:00:00 GMT Pharma Technology Focus – Issue 45 http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-45-4850481/ http://www.drugdevelopment-technology.com/features/featurepharma-technology-focus-issue-45-4850481/ In this issue: Israel’s pharma market, what Brexit would mean for clinical research in the UK, developments in obstetrics, the trouble with inhalable insulin, the FDA’s new support for innovation in manufacturing, plant-based vaccine manufacturing an… Tue, 29 Mar 2016 14:15:00 GMT